// STATE LEGISLATION TRACKER

Pennsylvania SB 866 — An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Pennsylvania
Bill: SB 866
Filed: 2025-07-24
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Pennsylvania SB866 appears to amend the state's controlled-substance law by changing controlled-substance schedules. Based only on the title and available metadata, it does not appear to target peptides, compounding, telehealth, NP/naturopath scope, or off-label prescribing.

Key Points

No clear peptide-specific language is available from the title or subjects
Main relevance is whether any peptide-like drug is added to a controlled schedule
No visible impact on 503A or 503B compounding from the available metadata
No visible change to telehealth or prescribing scope from the available metadata

What to Watch For

Note Watch the actual bill text for any named substances that overlap with peptide or hormone clinics.

Concern If a commonly used compound is scheduled, prescribing, dispensing, and monitoring rules could tighten.

Note The latest action was not available from the provided source, so process status is unclear.

Where the Bill Stands

The provided OpenStates record says the latest action refetch failed, so the bill's current stage cannot be confirmed from the available metadata.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws